glp-1 agonists blindness risk The Effect of Semaglutide and RAs on of Nonarteritic Anterior Ischemic Optic Neuropathy The Role of GLP-1RA Medications

In 2020 the first small-molecule structure (Zhao et al) revealed a druggable transmembrane sub-pocket distinct from the peptide-binding interface

Studies in patients with type 2 diabetes and obesity have demonstrated that the use of SGLT2 inhibitors, particularly empagliflozin, not only increases overall cancer risk but also significantly elevates the risk of bladder cancer [10, 108]

We only include drugs in development that have reported effects on weight loss

A robust sandwich covariance matrix estimator was used in the Cox model analyses to account for the re-use of stable use sets of insulin in the matching for GLP-1RA users (Additional file 1: Fig

GLP-1 Drugs Approved in the United States Below is the current list of major FDA-approved GLP-1 drugs in the United States, organized by active ingredient